1. Introduction {#S6}
===============

The global landscape of immunisation has changed considerably during the past two decades. New and considerably more expensive vaccines are becoming increasingly available in high-income countries (HIC) while adoption patterns are accelerating in low- and middle-income countries (LMIC). In LMIC this has been aided by substantial donor support, such as funds from Gavi, the Vaccine Alliance, for both strengthening the Expanded Programme for Immunisation (EPI) and for adopting new and underutilised vaccines \[[@R1]\]. However, decision-makers in both HIC and LMIC face an array of questions about which vaccines to prioritise given their limited budgets. WHO recommends that national vaccine policy is guided by National Immunisation Technical Advisory Groups (NITAGs) \[[@R2]\]. However, NITAGs also face difficulties in assimilating an ever-increasing amount of information. Hence, the need for collating and synthesising the available evidence to support decision-making in vaccine-related policy.

During the past decade, the number of scientific research articles and systematic reviews on vaccines has risen substantially. Consequently, there is a need for tools to filter this evidence and present it on an accessible platform. Systematic reviews are a particularly efficient means of summarising evidence for decision-makers because they use clear, transparent methods for combining evidence from multiple studies. This means decision-makers do not need to identify, appraise and synthesise findings from numerous individual studies themselves \[[@R3]\]. Systematic reviews aim to answer specific questions in order to minimise bias and present pre-filtered evidence for researchers and decision-makers \[[@R4],[@R5]\].

At present, systematic reviews on vaccine-related questions are not coordinated, either in terms of commissioning or dissemination. Unless decision-makers specifically commission a review, there is currently no process to ensure that proposed systematic review topics respond to their information needs, which may differ from one decision-maker to another. This not only leads to gaps in knowledge if particular questions are neglected, but also to duplication and overlap. Therefore, many NITAGs commission reviews to inform them, which leads to duplication \[[@R6]--[@R11]\]. At present, there is no common understanding of what vaccine-relevant systematic reviews have, or have not, been conducted. It is therefore unclear where duplication is a risk, or which areas have been neglected. Ideally, NITAGs should be able to ensure prior to commissioning that no similar reviews are planned, ongoing or have been published.

To date there is no singe repository where decision-makers can find systematic reviews conducted on topics relevant to vaccination policy. Identifying reviews on a specific topic requires time, skills in literature searching and access to academic databases. To facilitate this, the London School of Hygiene and Tropical Medicine, with funding from the National Institute for Health Research (NIHR), has created a database of vaccine policy-relevant systematic reviews (including both completed reviews and protocols) (SYSVAC). The database is hosted by the World Health Organization (WHO), who took over the NITAG resource centre ([www.nitag-resource.org](http://www.nitag-resource.org/)) from the Agence de Médicine Préventive (AMP) and is updated quarterly.

This paper presents a bibliometric analysis of the reviews included in this database. Bibliometric analysis aims to quantitatively characterise the literature, rather than to examine its findings \[[@R12]\]. The objectives of this paper are: (i) to describe the development of the SYSVAC database, (ii) to provide an overview of the vaccine-related systematic review literature by describing the trends in time, topic, area of focus, population and geographic location of published systematic reviews relevant to vaccine policy published between 1 January 2008 and 31 December 2016.

2. Material and methods {#S7}
=======================

In the remaining text the word systematic review will be used for both completed systematic reviews as well as systematic review protocols.

2.1. Development of the SYSVAC database {#S8}
---------------------------------------

Systematic reviews on vaccine- and immunization-related topics were identified through searches carried out in MEDLINE, Embase, the Cochrane Library (systematic reviews and Health Technology Assessments only), Scopus, Web of Science, Global Health and the PROSPERO International prospective register of systematic reviews \[[@R13]\]. PROSPERO is unique in that it includes the description of not only completed but also ongoing and planned systematic reviews. The final search was conducted in January 2017. Search terms specific to vaccines and immunisation were combined with filters designed to retrieve systematic reviews. The entries were restricted to a publication date from 1 January 2000 to 31 January 2017. Vaccine-related search terms were adapted to each database from the filters used in the National Institute of Health and Care Excellence Guidelines PH21 \[[@R14]\]. Search filters specific to systematic reviews were adapted from the Canadian Agency for Drugs and Technologies in Health strategy for searches on the Ovid platform \[[@R15]\] in the initial search. However, for the updates, the more specific BMJ search filter was used for Medline and Embase \[[@R16]\] and adapted for the other databases. The reason for this change was that the updates aimed to retrieve the more recent systematic reviews only, so a broader filter was no longer needed. In contrast to the early days of systematic reviewing, when a range of terms may have been used to describe the method, there is now a greater consensus on how to present, report and describe systematic reviews so omitting less specific terms does not lead to a loss in sensitivity. Wherever possible, searches were limited to title, keyword and abstract fields and to research involving human subjects. The full list of search terms used for each database can be found in [supplementary file 1](#SD2){ref-type="supplementary-material"}.

For each set of search results, duplicate references were removed and titles and abstracts were screened using predefined inclusion criteria. To be included in the database, articles had to meet the following criteria: (1) be a systematic review; (2) focus on human subjects; (3) focus on preventive vaccines, rather than vaccines for treatment or immunotherapy; (4) have a publication date on or after 1st January 2008 (see [supplementary file 1](#SD2){ref-type="supplementary-material"} for more details). In addition, the analysis presented here is restricted to reviews published on or before the 31st of December 2016. (5) Not focus on vaccine development; and (6) not be withdrawn. Full texts of the papers were not retrieved during the screening. All systematic reviews meeting the inclusion criteria were combined into one Endnote database (Thomson Reuters 2014) and duplicates were removed.

Because of the size of the database, all entries were indexed using keywords for ease of categorisation. A keyword coding protocol was developed, pre-tested and refined by two researchers (SF and HB), with input from staff at AMP. Keywords enabled entries to be assigned to categories in five areas: (1) pathogen or disease, e.g. varicella; (2) target population, e.g. adolescents, pregnant women; (3) geographical location according to WHO regions \[[@R17]\]; (4) country income group according to the World Bank list of economies published July 2015 \[[@R18]\] and (5) topic area, e.g. immunology. An exhaustive list of all keywords can be found in [supplementary file 1](#SD2){ref-type="supplementary-material"}. Keywords were not mutually exclusive and articles could be classified with multiple keywords or none from each category. Any queries during the screening and coding process were resolved by consensus between two researchers (SF and HB).

2.2. Data analysis {#S9}
------------------

The database content was exported from Endnote X7 to Excel 2016. Data classifications were checked and cleaned. The database was analysed by year of publication, journal and keywords. Trends over time were explored for the disease/pathogen keyword category. As a comparison to general biomedical research output, we explored the number of records published in PubMed per year in general and records containing "systematic review" in title or abstract. Further we examined annual numbers of systematic reviews registered in Prospero (a systematic review register launched in 2011) in general and records containing 'vaccin\*' or 'immuni\*' in title/abstract or keywords.

For the main disease/pathogen and topic areas, titles and abstracts were compared to ascertain any two or more reviews on identical or overlapping topics.

3. Results {#S10}
==========

3.1. Search results {#S11}
-------------------

All searches combined identified 29,078 references. After removing duplicates, 15,064 records remained and after screening, 1285 unique systematic reviews and protocols were included in the database and analysis. The full details are shown in the PRISMA flow diagram in [Fig. 1](#F1){ref-type="fig"}.

3.2. Most relevant journals {#S12}
---------------------------

The 1285 unique systematic reviews were published in 398 separate academic journals as well as the Cochrane databases, most commonly "Vaccine" (N = 153) and the "Cochrane systematic review database" (N = 82).

3.3. Trends over time {#S13}
---------------------

The number of systematic reviews identified per year on vaccine-related topics increased steadily from 34 in 2008 to 322 in 2016 (see [Fig. 2](#F2){ref-type="fig"}), a more than ninefold increase. During the same period the total number of articles indexed on PubMed increased by 50% from 835,946 in 2008 to 1,255,235 in 2016. PubMed records containing "systematic review" in either the title or abstract increased 5-fold from 3456 in 2008 to 17,691 in 2016. The number of reviews (on any topic) registered on Prospero increased by almost 30 times from 284 in 2011 to 8162 in 2016. However, vaccine-related review registrations lagged behind this general trend, with only three identified in 2011 and 53 in 2016 -- an almost 18-fold increase (for more details, see [supplementary file 2.1, Tables S1 and S2](#SD1){ref-type="supplementary-material"}).

3.4. Disease/pathogen areas {#S14}
---------------------------

The database was analysed for 48 specific disease/pathogen areas ranging alphabetically from Adenovirus to Zika virus (see [supplementary file 1](#SD2){ref-type="supplementary-material"}). [Table 1](#T1){ref-type="table"} shows the number of systematic reviews for each disease/pathogen. Out of 1285 systematic reviews, 312 (24%) were conducted on a general immunisation topic, while 973 (76%) focused on disease/pathogen specific topics, of which 859 (88%) concentrated on one disease/pathogen area and 114 (12%) on two or more. For six disease/pathogen areas at least 50 systematic reviews were identified: influenza (N = 260; 20%), human papilloma virus (HPV) (N = 173; 13%), pneumococcus (N = 145; 11%), hepatitis B (N = 96; 7%), rotavirus (N = 54; 4%) and measles (N = 50; 4%). [Fig. 3](#F3){ref-type="fig"} shows the trend over time for these six disease/pathogen areas, all of which exhibit a general upwards trend in the annual number of systematic reviews. The increase in numbers of systematic reviews was steepest for influenza, HPV and pneumococcus. Annual numbers of systematic reviews for hepatitis B seem to have plateaued in the past two years. On the other hand, there appears to have been a sharp increase in measles systematic reviews in 2016. For influenza, there is a peak in the years 2012 and 2013, shortly after the 2009/2010 H1N1 pandemic; the time lag may reflect the time taken to commission, conduct and publish systematic reviews.

3.5. Topic area {#S15}
---------------

[Fig. 4](#F4){ref-type="fig"} shows the number of systematic reviews by topic area. A large number focused on epidemiology (N = 537, 42%), safety/pain (N = 414, 32%) and immunology (N = 281, 22%). These topic areas were followed by coverage (N = 225, 18%), economic studies (N = 147, 11%) and knowledge, attitude, behaviour & acceptability (N = 113, 9%).

3.6. Geography and country income {#S16}
---------------------------------

Most reviews did not focus on a specific region of the world (N = 1096, 85%). Out of the 189 (15%) articles with a geographical focus, 171 (90%) concentrated on one specific region and 18 (10%) on more than one specific region. Of the 189 systematic reviews with a geographical restriction, the commonest target was Europe with 61 (32%) articles, followed by Western Pacific and the Americas with 45 (24%) and 51 (27%) articles, respectively. Lastly, a smaller number of reviews focused on Africa and South-East Asia (both N = 24, 13%), as well as the Eastern Mediterranean region (N = 16, 8%) (see Fig. S1 in [supplementary file 2](#SD1){ref-type="supplementary-material"}).

The majority of reviews (N = 1061, 83%) were not restricted to a specific country income group. Of the 224 (17%) reviews that had this focus, 145 (65%) concentrated on one and 79 (35%) on more than one country income group, with 121 (54%) focusing on middle-income countries, 105 (47%) on high-income countries and 83 (37%) on low-income countries (see Fig. S2 in [supplementary file 2](#SD1){ref-type="supplementary-material"}).

3.7. Population focus {#S17}
---------------------

Reviews focused on different age groups and specific populations of interest. A total of 524 (41%) reviews did not specify any focal population group, while 504 (39%) focused on one group, and 257 (20%) on more than one particular population group. [Fig. 5](#F5){ref-type="fig"} shows that the most common focal age group was 0--9 years (N = 369, 29%). Eleven percent (N = 146) of reviews focused on adults, 8% (N = 101) on 10--18 year olds and 5% (N = 69) on older adults aged 65 or more. Other focal populations included risk groups (N = 189, 15%), health care workers (N = 76, 6%), parents/care givers (N = 73, 6%), and pregnant women (N = 62, 5%).

3.8. Repetition and overlap of reviews {#S18}
--------------------------------------

There appeared to be a number of overlapping review topics. To highlight some of them, we looked at reviews on influenza and HPV in more detail. Among 260 systematic reviews looking at influenza, 17 focused on influenza vaccination during pregnancy and 13 of these looked at safety and adverse birth outcomes, ten at efficacy or effectiveness and two at coverage or determinants of coverage. In the year 2015, four systematic reviews were conducted on almost identical topics looking at the association between maternal influenza vaccination and negative birth outcomes, including stillbirth, spontaneous abortion, fetal death, preterm delivery and congenital malformation \[[@R19]--[@R22]\]. Thirty-six systematic reviews published between 2009 and 2016 looked at influenza vaccination among health care workers, 27 of which focused on uptake and its determinants as well as attitudes towards influenza vaccination and 17 on safety, efficacy or effectiveness outcomes. Out of the 173 reviews found on HPV, 28 reported on economic outcomes, with 16 synthesizing evidence on the cost-effectiveness of HPV vaccine when targeting females. There was also a substantial overlap of reviews in other topic areas of HPV vaccination, including epidemiology, immunology, safety, coverage and knowledge, attitudes & behaviour.

4. Discussion {#S19}
=============

The analyses presented in this paper show the substantial growth of systematic reviews on vaccine research during the past nine years, with annual numbers increasing more than ninefold from 2008 to 2016. Several factors may have contributed to this increase. Expansion in primary research may have augmented the number of potential systematic reviews. Over the past decade, a greater interest in vaccine research has developed, supported by more research funding \[[@R1],[@R23]\], as well as broader availability of vaccines worldwide. Systematic reviews have become an increasingly popular method, with more being conducted in all fields, not just on vaccines. This may be the result of a wider recognition of the value of systematic reviews. While the annual number of records in PubMed containing the term "systematic review" has grown at a similar rate to the numbers in our database (130% and 145% average annual increase), the increase in output of general biomedical research was at a slower speed (106% average annual increase). The "Prospero" database, which registers systematic reviews, has seen an almost exponential increase (260% average annual increase) in numbers of annual records from 2011, the year of its inception, to 2016. However, it appears that vaccine-related records on Prospero increased at a slower rate (210% average annual increase), suggesting the recent popularity of systematic reviews as the primary driver of the annual increase in records on our database, rather than the more modest increase in vaccine-related literature. While there are now a large number of vaccine-relevant systematic reviews available or planned, it nevertheless seems that the field has a smaller secondary research output than other health-related topics.

As more systematic reviews are being conducted, the potential for duplication and overlap rises. We found numerous examples of reviews in very similar areas in the field of vaccination. Given the considerable time, effort and resources required to conduct a systematic review, such apparent duplication may be an inefficient use of resources. Before commencing a systematic review, as a first step to avoid duplication, reviewers should ideally confirm that there are no currently planned or completed systematic reviews on a similar topic using Prospero or SYSVAC. Thereafter, the commissioning NITAGs or the reviewers themselves should register their systematic review on Prospero at the start of their undertaking. A risk of duplication still exists for reviews that are planned or ongoing, but have not been registered on Prospero, because SYSVAC would only capture them in the next update following publication. More widespread use of Prospero and SYSVAC could improve efficiency, obviate duplication and potentially facilitate pooling of resources. Equally important to transparent planning of systematic reviews is choosing topics wisely and purposively. Decision-makers often lack crucial evidence required to support or reject policies. Systematic reviews can be of great use in the decision-making process, but without coordination and differentiation between researchers, funders and decision-makers, resources will not be used efficiently. Improving communication among the different stakeholders will increase efficiency. Key figures from different stakeholder groups could then develop a process to reach consensus about which review topics to pursue. A starting point would be to use the SYSVAC database and Prospero to identify which reviews have already been conducted or are planned. Such a process might open the possibility of pooling resources and collaborations among different groups. The involvement of decision-makers in topic selection should help ensure the topics are of use to them, which would ultimately benefit the people and communities being studied.

The SYSVAC database and this bibliometric analysis have a number of limitations. Firstly, while decision makers will easily be able to identify relevant systematic reviews on SYSVAC, they will still need to conduct a thorough quality assessment of each review, followed by a synthesis of all reviews applicable to their specific question. Currently, there are a number of tools available to appraise the quality of systematic reviews. The PRISMA \[[@R24]\] and AMSTAR \[[@R25]\] checklists are well-known and tested tools to assess methodological quality of systematic reviews. However, to appraise the quality or relevance of a systematic review a broader framework is needed. The US Agency for Health Care Research and Quality has proposed a five-step approach for identifying, appraising relevance and methodological quality, analysing and using existing systematic reviews \[[@R26]\]. In addition to following the guidelines and checklists mentioned above, it is essential to involve experts in the field to translate review results into policy.

Secondly, while the present analysis identified a number of overlaps in review topics, it is unclear to what extent the methodology and results of these reviews are similar, as we only screened and coded based on the title and abstract. The user would need to assess this based on the specific question asked and scrutinize both methods and results of any reviews retrieved.

Decision-makers need to find systematic reviews easily if they are to use them. The SYSVAC database ([www.nitag-resource.org](www.nitag-resource.org)) is a freely available online database of vaccine-relevant systematic reviews aimed at decision-makers as a resource for quick reference, information and guidance. It should increase the ease with which vaccine-relevant systematic reviews can be identified so that decisions can be based on the best available evidence to maximise population health outcomes.

5. Conclusions {#S20}
==============

From 2008 to 2016 the number of vaccine-related systematic reviews published annually increased by over 9 times. There appears to be large potential for duplication, which could be reduced if intentions to conduct a systematic review were registered prospectively and existing reviews were searched prior to new review commissioning. Decision-makers can use the SYSVAC database ([www.nitag-resource.org](www.nitag-resource.org)) to search for systematic reviews on vaccine-related topics to inform their decision-making. The SYSVAC database could also be used as the focal point for the coordination of the commissioning of systematic reviews and the removal of duplication and inefficiency in evidence synthesis for vaccine policy.

Supplementary Material {#SM}
======================

Supplementary data associated with this article can be found, in the online version, at <https://doi.org/10.1016/j.vaccine.2018.02.049>.
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###### Number of systematic reviews by disease/pathogen.

  Disease/pathogen specific estimates                                                                                                                                                                                              
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------ ------
  Influenza                                                                                                                                                                                                                 260    20%
  Human papillomavirus                                                                                                                                                                                                      173    13%
  Pneumococcus                                                                                                                                                                                                              145    11%
  Hepatitis B                                                                                                                                                                                                               96     7%
  Rotavirus                                                                                                                                                                                                                 54     4%
  Measles                                                                                                                                                                                                                   50     4%
  Pertussis                                                                                                                                                                                                                 49     4%
  Tetanus toxoid                                                                                                                                                                                                            41     3%
  Varicella                                                                                                                                                                                                                 37     3%
  Tuberculosis                                                                                                                                                                                                              35     3%
  Rubella                                                                                                                                                                                                                   33     3%
  *Haemophilus influenzae* type b (Hib)                                                                                                                                                                                     32     2%
  Poliomyelitis                                                                                                                                                                                                             29     2%
  Herpes zoster                                                                                                                                                                                                             26     2%
  Diptheria                                                                                                                                                                                                                 25     2%
  Mumps                                                                                                                                                                                                                     23     2%
  Combination vaccine                                                                                                                                                                                                       19     1%
  Hepatitis A                                                                                                                                                                                                               18     1%
  Meningococcal infection                                                                                                                                                                                                   16     1%
  Cholera                                                                                                                                                                                                                   11     1%
  Yellow fever                                                                                                                                                                                                              10     1%
  Dengue                                                                                                                                                                                                                    8      1%
  Malaria, Rabies                                                                                                                                                                                                           7      1%
  Smallpox                                                                                                                                                                                                                  6      \<1%
  *Escherichia coli,* HIV (each)                                                                                                                                                                                            5      \<1%
  Japanese encephalitis                                                                                                                                                                                                     4      \<1%
  Hepatitis C, Leishmaniasis, *Salmonella* (each)                                                                                                                                                                           3      \<1%
  Adenovirus, Anthrax, *Coxiella burnetii* (Q fever), Ebola, *Shigella*, Tick-borne encephalitis, Typhoid (each)                                                                                                            2      \<1%
  *Campylobacter*, Enterovirus vaccine (hand foot and mouth), Herpes simplex, *Mycobacterium leprae*, *Mycobacterium vaccae*, *Pseudomonas aeruginosa*, Respiratory Syncytial Virus (RSV), *Streptococcus group B* (each)   1      \<1%
  **Summary estimates**                                                                                                                                                                                                            
  All systematic reviews                                                                                                                                                                                                    1285   100%
  On general vaccination/immunization topic                                                                                                                                                                                 312    24%
  On disease-specific topic                                                                                                                                                                                                 973    76%
  On one disease/pathogen area                                                                                                                                                                                              859    67%
  On two or more disease/pathogen area                                                                                                                                                                                      114    9%
